Polaryx Therapeutics, Inc. (PLYX) Stock Forecast
PLYX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.75 / 5 from 4 analysts
- Price target
- $7.50 average of analyst targets
- Upside to target
- +298.9% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.06
- 52-week range
- $1.87 – $35.00
PLYX analyst ratings
4 analystsNumber of analysts at each rating.
PLYX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
PLYX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.05 | −$0.06 | −$0.03 | — | — | 4 |
| Current fiscal year (2026) | −$0.20 | −$0.22 | −$0.15 | −$0.20 | +2.5% | 4 |
| Next fiscal year (2027) | −$0.29 | −$0.31 | −$0.26 | −$0.20 | −47.4% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
PLYX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | — | 4 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 4 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 4 |
PLYX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
PLYX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.03 | −$0.03 | −$0.06 | −$0.04 | −$0.05 | +58.3% | 0 up · 0 down |
| Current fiscal year (2026) | −$0.12 | −$0.12 | −$0.22 | −$0.20 | −$0.20 | +62.5% | 0 up · 0 down |
| Next fiscal year (2027) | −$0.28 | −$0.28 | −$0.28 | −$0.27 | −$0.29 | +2.7% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
PLYX earnings surprises
Reported EPS vs the consensus estimate for the last 3 quarters; PLYX beat in 1 of 3.
What analysts expect from PLYX
4 analysts cover Polaryx Therapeutics; their consensus rating is strong buy (4.75 on a 1–5 scale, where 5 is a strong buy). The average price target is $7.50, 298.9% above the latest close of $1.88. Analysts expect earnings of −$0.20 per share for 2026, +2.5% from a year earlier. For 2027 the average estimate is −$0.29 per share. Polaryx Therapeutics beat the EPS estimate in 1 of the last 3 quarters.
Related: PLYX income statement, PLYX key metrics, PLYX chart. See the PLYX stock overview for the latest quote and news.
PLYX forecast FAQ
What is Polaryx Therapeutics's price target?
The average analyst price target for Polaryx Therapeutics is $7.50, 298.9% above the latest close of $1.88.
Is Polaryx Therapeutics a buy, hold or sell?
Of 4 analysts covering Polaryx Therapeutics, 3 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Polaryx Therapeutics's EPS forecast?
Analysts forecast −$0.20 per share for 2026 (range −$0.22 to −$0.15); for 2027 the estimate is −$0.29.
When does Polaryx Therapeutics report earnings?
Polaryx Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026; the EPS estimate is $-0.06.
Does Polaryx Therapeutics usually beat earnings estimates?
Polaryx Therapeutics reported EPS at or above the analyst estimate in 1 of the last 3 quarters.